News

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

How will AI influence psychiatry training?

Being a fool can run from being thought to be inappropriately silly to Shakespeare’s fools of creative wisdom. Where does psychiatry come in?

Continuity vs discontinuity, tradition vs change in the “psy disciplines.”

Check out the pipeline updates from March!

Further data shared on LB-102 for schizophrenia.

A panel of experts presented new consensus recommendations focused on the screening, diagnosis, and treatment of tardive dyskinesia among older adults in long-term care settings.

Tazbentetol interim results show improvement in schizophrenia symptoms.

ASAM announces new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment.

Why men struggle in silence: suicide risks, hidden depression signs, and practical ways therapy and connection help.

How medical conferences cut carbon footprint: greener travel, water stations, compostables, recycled badges, and offsets—AAP’s 2025 model.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

Learn more about why shared decision-making fails across cultures—and how a quick wind-check helps clinicians adapt recovery care without losing trust.

Resort thrillers glamorize hotel killings, but data reveals a quieter risk: planned suicides by local guests—and warning signs clinicians can spot.

New lawsuits target social media and chatbots that could reshape AI regulation and protect youth mental health.

Near 80, a psychiatrist rediscovers joy in family, music, and purpose—while facing mortality and the bittersweet truths of aging.

AD/PD 2026 highlights oral blarcamesine preserving brain volume and IV lecanemab sustaining use while clearing amyloid-beta.

Learn how clinicians distinguish grief from depression, when sadness turns impairing, and which therapies and meds help people heal after loss.

Experts discuss diagnostic validators and the DSM.

As US leaders and psychiatrists age past 80, Erikson’s ninth stage reveals how wisdom, burnout, and politics shape national mental health.

In this CME article, learn how proactive ICU psychiatry reduces delirium, length of stay, and readmissions while advancing equity and value-based critical care.

Eid, Nowruz and the equinox highlight renewal as war fuels trauma, hate and a need for mental health resilience and interfaith healing.

Preparing children for vicissitudes and losses and for the mystery, magic, and poetry of life.

Explore how “luck” shapes mental health, trauma recovery, and doctor-patient fit—while revealing why personal choices still drive outcomes like A1C.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

This article unpacks narcissistic personality disorder, from grandiose fantasies to vulnerable traits, and explains why ‘narcissist’ is often misused online.

Discover how psychodynamic therapy and modern antipsychotics can reduce psychotic symptoms, restore meaning, and improve quality of life for patients with schizophrenia.

Early-life immigration may heighten dementia risk yet build resilience.